Sentences with phrase «cell lead candidate»
Juno's setbacks contrast with the biologics license application planned this year by Novartis, and the rolling BLA in progress by Kite Pharma — which on Tuesday reported positive 6 - month trial data for its CAR T - cell lead candidate.
https://www.genengnews.com/ Not exact matches
This company's lead candidate, trilaciclib, is intended to prevent the blood cell devastation often caused by standard chemotherapies, and it appears to do the trick.
«Simply put, the compound turns - off the sperm's ability to swim, significantly limiting fertilization capabilities,» said lead investigator Michael O'Rand, PhD, retired professor of cell biology and physiology in the University of North Carolina at Chapel Hill School of Medicine, and president / CEO of Eppin Pharma, Inc. «This makes EP055 an ideal candidate for non-hormonal male contraception.»
The former Speaker — now a leading candidate for the Republican presidential nomination — talked to DISCOVER in 2006 about evolution, stem cells, Washington's two cultures, and why kids should be paid to take science and math.
«The bulk of the world's cellulose is produced within the thickened secondary cell walls of tissues hidden inside the plant body,» says University of British Columbia Botany PhD candidate Yoichiro Watanabe, lead author of the paper published this week in Science.
«Now, because we know the resistance mechanism, we can design elements to minimize the emergence of resistance as these promising new drug candidates are developed,» said Ben Shen, a TSRI professor who led the study, which was published February 20, 2014 online ahead of print by the Cell Press journal Chemistry & Biology.
In a development that could lead to a new generation of drugs to precisely treat a range of diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time designed a drug candidate that decreases the growth of tumor cells in animal models in one of the hardest to treat cancers — triple negative breast cancer.
Dr. Kirino says that «further studies to understand how SHOT - RNAs promote cell proliferation may lead to the use of SHOT - RNAs as potential target candidates for future therapeutic applications in breast and prostate cancers.»
An alternative approach, most common for anti-infectives, is to use compounds («phenotypic inhibitors») which have already been shown to be active against the target organism in the living pathogenic cell as chemical leads for improvement by Medicinal Chemistry, towards systemically active Candidate Drugs.
ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead product candidate VC - 01 in patients with type 1 diabetes who have minimal to no insulin - producing beta cell function.
The scientists focused on bismuth vanadate, a thin - film semiconductor that has emerged as a leading candidate for use as a photoanode, the positively charged part of a photoelectric cell that can absorb sunlight to split water.
«We found that HbA1c was systematically lower in African - Americans with sickle cell trait than those without sickle cell trait despite similar blood sugar measurements using other tests,» says lead author Mary Lacy, a doctoral candidate at the Brown School of Public Health.
Our lead candidate, LYS - GM101, has been designed to replace this defective gene in the cells of GM1 patients, in order to allow for production of the functional lysosomal acid beta - galactosidase (bgal) enzyme.
They selected the combinations of backbone mutations that supported better growth in cell culture, identifying two candidate backbones that led to higher amounts of vaccine virus.
The company's lead candidate, GLN - 1001, is a first - in - class, orally available oncolytic small molecule, currently being developed as a potentially disease modifying therapy for glioblastoma by targeting specific vulnerabilities in tumor cells.
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
The Company's lead product candidate, VC - 01, is based on the production of pancreatic progenitors derived from human pluripotent stem cells.
ViaCyte is conducting a Phase 1/2 clinical trial, called STEP ONE, of the Company's lead product candidate VC - 01 in patients with T1D who have minimal to no insulin - producing beta cell function.
Lead study author and doctoral candidate Molly Derry commented «We've known for quite a while that the bioactive compounds in grape seed extract selectively target many types of cancer cells.